Matches in SemOpenAlex for { <https://semopenalex.org/work/W3168680032> ?p ?o ?g. }
- W3168680032 endingPage "3329" @default.
- W3168680032 startingPage "3329" @default.
- W3168680032 abstract "Parkinson’s disease (PD) is characterized mainly by the loss of dopaminergic neurons in the substantia nigra (SN) mediated via oxidative stress. Although glutaredoxin-1 (GLRX1) is known as one of the antioxidants involved in cell survival, the effects of GLRX1 on PD are still unclear. In this study, we investigated whether cell-permeable PEP-1-GLRX1 inhibits dopaminergic neuronal cell death induced by 1-methyl-4-phenylpyridinium (MPP+) and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). We showed that PEP-1-GLRX1 protects cell death and DNA damage in MPP+-exposed SH-SY5Y cells via the inhibition of MAPK, Akt, and NF-κB activation and the regulation of apoptosis-related protein expression. Furthermore, we found that PEP-1-GLRX1 was delivered to the SN via the blood–brain barrier (BBB) and reduced the loss of dopaminergic neurons in the MPTP-induced PD model. These results indicate that PEP-1-GLRX1 markedly inhibited the loss of dopaminergic neurons in MPP+- and MPTP-induced cytotoxicity, suggesting that this fusion protein may represent a novel therapeutic agent against PD." @default.
- W3168680032 created "2021-06-22" @default.
- W3168680032 creator A5016856532 @default.
- W3168680032 creator A5020749064 @default.
- W3168680032 creator A5027123155 @default.
- W3168680032 creator A5031878697 @default.
- W3168680032 creator A5033527837 @default.
- W3168680032 creator A5041813523 @default.
- W3168680032 creator A5046507249 @default.
- W3168680032 creator A5057554500 @default.
- W3168680032 creator A5077999831 @default.
- W3168680032 creator A5078229156 @default.
- W3168680032 creator A5078284228 @default.
- W3168680032 creator A5082202159 @default.
- W3168680032 creator A5088713039 @default.
- W3168680032 creator A5089399529 @default.
- W3168680032 date "2021-06-01" @default.
- W3168680032 modified "2023-09-26" @default.
- W3168680032 title "PEP-1-GLRX1 Reduces Dopaminergic Neuronal Cell Loss by Modulating MAPK and Apoptosis Signaling in Parkinson’s Disease" @default.
- W3168680032 cites W1578882407 @default.
- W3168680032 cites W1587360940 @default.
- W3168680032 cites W1598978469 @default.
- W3168680032 cites W1805244695 @default.
- W3168680032 cites W1933803332 @default.
- W3168680032 cites W1942214720 @default.
- W3168680032 cites W1969496633 @default.
- W3168680032 cites W1970203053 @default.
- W3168680032 cites W1971389338 @default.
- W3168680032 cites W1975287242 @default.
- W3168680032 cites W1976957140 @default.
- W3168680032 cites W1977252372 @default.
- W3168680032 cites W1988622364 @default.
- W3168680032 cites W1990056937 @default.
- W3168680032 cites W1991505929 @default.
- W3168680032 cites W2000076612 @default.
- W3168680032 cites W2002410880 @default.
- W3168680032 cites W2006659891 @default.
- W3168680032 cites W2013449217 @default.
- W3168680032 cites W2013713870 @default.
- W3168680032 cites W2014495684 @default.
- W3168680032 cites W2018679722 @default.
- W3168680032 cites W2026484283 @default.
- W3168680032 cites W2033082385 @default.
- W3168680032 cites W2034878251 @default.
- W3168680032 cites W2053900971 @default.
- W3168680032 cites W2066650823 @default.
- W3168680032 cites W2066762007 @default.
- W3168680032 cites W2068187936 @default.
- W3168680032 cites W2068336834 @default.
- W3168680032 cites W2069066285 @default.
- W3168680032 cites W2069689505 @default.
- W3168680032 cites W2072548440 @default.
- W3168680032 cites W2072943838 @default.
- W3168680032 cites W2083262462 @default.
- W3168680032 cites W2087445487 @default.
- W3168680032 cites W2091834895 @default.
- W3168680032 cites W2092462980 @default.
- W3168680032 cites W2093758184 @default.
- W3168680032 cites W2103056038 @default.
- W3168680032 cites W2105668301 @default.
- W3168680032 cites W2106607757 @default.
- W3168680032 cites W2111682630 @default.
- W3168680032 cites W2118165360 @default.
- W3168680032 cites W2123627993 @default.
- W3168680032 cites W2130623349 @default.
- W3168680032 cites W2142219833 @default.
- W3168680032 cites W2143959688 @default.
- W3168680032 cites W2144367399 @default.
- W3168680032 cites W2165445583 @default.
- W3168680032 cites W2168819285 @default.
- W3168680032 cites W2333915371 @default.
- W3168680032 cites W2339791932 @default.
- W3168680032 cites W2600495731 @default.
- W3168680032 cites W2611169084 @default.
- W3168680032 cites W2797560790 @default.
- W3168680032 cites W2801937771 @default.
- W3168680032 cites W2808273638 @default.
- W3168680032 cites W2947461527 @default.
- W3168680032 cites W2954304338 @default.
- W3168680032 cites W2986046905 @default.
- W3168680032 cites W3009087776 @default.
- W3168680032 cites W4293247451 @default.
- W3168680032 cites W62603772 @default.
- W3168680032 doi "https://doi.org/10.3390/molecules26113329" @default.
- W3168680032 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8198499" @default.
- W3168680032 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34206041" @default.
- W3168680032 hasPublicationYear "2021" @default.
- W3168680032 type Work @default.
- W3168680032 sameAs 3168680032 @default.
- W3168680032 citedByCount "5" @default.
- W3168680032 countsByYear W31686800322022 @default.
- W3168680032 countsByYear W31686800322023 @default.
- W3168680032 crossrefType "journal-article" @default.
- W3168680032 hasAuthorship W3168680032A5016856532 @default.
- W3168680032 hasAuthorship W3168680032A5020749064 @default.
- W3168680032 hasAuthorship W3168680032A5027123155 @default.
- W3168680032 hasAuthorship W3168680032A5031878697 @default.
- W3168680032 hasAuthorship W3168680032A5033527837 @default.